KRYS Krystal Biotech Inc

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington.

Poster presentation details are as follows:

Title: An HSV-1-Based Vector Platform for Localized Delivery to the Posterior of the EyePresenter: Haley Nicole CartwrightDate and Time: May 7, 2024 from 3:30PM to 5:15PM PTPosterboard Number: B0022Abstract Number: 3978 - B0022

The poster will be available to conference attendees. Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACTInvestors and Media:                                                              Stéphane Paquette, PhDKrystal Biotechspaquette@krystalbio.com